Raquel Rodríguez-López

Dr. Raquel Rodríguez-López

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2015 in Molecular Genetics and Genomics
Verified
Journal Article
Closed access
PDF file
DADavid Albuquerque
David Albuquerque
ESEric Stice
Eric Stice
RRRaquel Rodríguez-López
Raquel Rodríguez-López
LMLicínio Manco
Licínio Manco
CNClévio Nóbrega
Clévio Nóbrega

21 August 2003 in Human Mutation
Verified
Journal Article
Closed access
PDF file
ODOrland Diez
Orland Diez
ACAna Osorio Cabrero
Ana Osorio Cabrero
MDMercedes Durán
Mercedes Durán
JMJosé Ignacio Martinez-Ferrandis
José Ignacio Martinez-Ferrandis
MHMiguel de la Hoya
Miguel de la Hoya
MBMontserrat Baiget
Montserrat Baiget
We screened index cases from 410 Spanish breast/ovarian cancer families and 214 patients (19 of them males) with breast cancer for germ‐line mutations in the BRCA1 and BRCA2 genes, using SSCP, PTT, CSGE, DGGE, and direct sequencing. We identified 60 mutations in BRCA1 and 53 in BRCA2. Of the 53 distinct mutations observed, 11 are novel and 12 have been reported only in Spanish families (41.5%). The prevalence of mutations in this set of families was 26.3%, but the percentage was higher in the families with breast and ovarian cancer (52.1%). The lowest proportion of mutations was found in the site‐specific female breast cancer families (15.4%). Of the families with male breast cancer cases, 59.1% presented mutations in the BRCA2 gene. We found a higher frequency of ovarian cancer associated with mutations localized in the 5′ end of the BRCA1 gene, but there was no association between the prevalence of this type of cancer and mutations situated in the ovarian cancer cluster region (OCCR) region of exon 11 of the BRCA2 gene. The mutations 187underscore;188delAG, 330A>G, 5236G>A, 5242C>A, and 589underscore;590del (numbered after GenBank U14680) account for 46.6% of BRCA1 detected mutations whereas 3036underscore;3039del, 6857underscore;6858del, 9254underscore;9258del, and 9538underscore;9539del (numbered after GenBank U43746) account for 56.6% of the BRCA2 mutations. The BRCA1 330A>G has a Galician origin (northwest Spain), and BRCA2 6857underscore;6858del and 9254underscore;9258del probably originated in Catalonia (northeast Spain). Knowledge of the spectrum of mutations and their geographical distribution in Spain will allow a more effective detection strategy in countries with large Spanish populations. Hum Mutat 22:301–312, 2003.

11 April 2002 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
ACAna Osorio Cabrero
Ana Osorio Cabrero
MHMiguel de la Hoya
Miguel de la Hoya
RRRaquel Rodríguez-López
Raquel Rodríguez-López
AMAngel Martínez‐Ramírez
Angel Martínez‐Ramírez
ACAlicia Cazorla
Alicia Cazorla
JBJavier Benítez
Javier Benítez
The BRCA1 and BRCA2 genes are responsible for a high proportion of familial breast cancer; germline mutations in these genes confer a lifetime risk of about 70% for developing breast cancer. Most of the described deleterious mutations are small deletions or insertions that originate a truncated protein; however, in many cases, they are amino acid changes whose significance is unknown. In these cases, there are some tests that can analyze the meaning of these variants, but most remain unclassified. The BRCA genes are tumor supressors and it is beleived that complete loss of the wild‐type allele is a common mechanism of inactivation in tumors from patients carrying a germline deleterious mutation in these genes; if this is true, loss of heterozygosity (LOH) analysis in the tumor sample could help to distinguish if a rare variant is either a deleterious mutation or a common polymorphism. In the present study, we performed LOH analysis at the BRCA loci in 47 tumors from patients who belonged to high‐risk breast cancer families and were carriers of any type of alteration in these genes. Our results suggest that (i) loss of the wild‐type allele is the most common mechanism of inactivation in tumors from patients who carry a deleterious mutation in any of the genes, (ii) this loss is not common when we analyze familial tumors not associated with mutations in BRCA and (iii) LOH can be used to clarify variants of unknown significance in the BRCA genes.

7 October 2003 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
ACAna Osorio Cabrero
Ana Osorio Cabrero
RRRaquel Rodríguez-López
Raquel Rodríguez-López
ODOrland Diez
Orland Diez
MHMiguel de la Hoya
Miguel de la Hoya
JMJosé Ignacio Martínez
José Ignacio Martínez
JBJavier Benítez
Javier Benítez
Searching for low‐penetrance genes involved in breast cancer susceptibility has been a field of interest in the last few years. Recently, the CHEK 2 gene, involved in DNA damage and replication checkpoints, has been pointed out as a good candidate; moreover, a specific variant in this gene,1100delC, has been found to increase breast cancer susceptibility among familial breast cancer cases not attributable to mutations in BRCA1 or BRCA2 genes. In our present study, we evaluated the role of the 1100delC variant as a susceptibility allele in breast cancer in the Spanish population. However, our results suggest that this variant is absent or very infrequent in our population, making its screening irrelevant from the practical point of view.


1 April 2012 in Obesity
Verified
Journal Article
Open access
PDF file
JGJuan R. González
Juan R. González
MGMarta González‐Carpio
Marta González‐Carpio
RHRosario Hernández‐Sáez
Rosario Hernández‐Sáez
VVVictoria Serrano Vargas
Victoria Serrano Vargas
GHGuadalupe Torres Hidalgo
Guadalupe Torres Hidalgo
RRRaquel Rodríguez-López
Raquel Rodríguez-López
Childhood and adult obesity have been widely associated with FTO genetic variability in different populations. This study aimed to investigate the linkage disequilibrium (LD) block structure of a region surrounding the candidate rs9939609 SNP and determine the best single nucleotide polymorphism (SNP) combination that explains the higher proportion of variability observed in children with severe obesity, including obese subjects from families with a very high occurrence of obesity. A sliding window approach pointed to a block containing the rs1477196/rs17817449/rs9939609 haplotype (P value 3.1 × 10−8). Carriers of the GGA combination had an increased risk of obesity (odds ratio (OR) 2.07, 95% confidence interval (CI) 1.41–3.04, P = 2.0 × 10−4) with respect to those individuals with the reference ATT haplotype. A further SNP, rs9921255, also showed association with obesity (P = 8.3 × 10−4, OR 1.77; 95% CI 1.15–2.74 and OR 5.78; 95% CI 1.22–27.49 for heterozygotes and homozygotes, respectively) and did not segregate with the previously described risk haplotype. The calculation of risk score based on the GGA haplotype combined with the rs9921255 variant showed a much greater effect of the FTO gene on high BMI. This score yields an attributable risk of 34% for severe obesity, and the increased risk per risk allele was 1.71 (P = 1.0 × 10−6). We conclude that the description of this polymorphic combination in the FTO gene could be useful for the early identification of inherited susceptibility to weight‐gain since childhood, with a higher sensitivity than considering the effect of a single marker.